The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation
2018 · PharmacoEconomics - Open · 8 citations
https://doi.org/10.1007/s41669-017-0065-9
P
Peter Lichtlen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
102
Papers
1.6K
Citations
21
h-index
30
i10-index
Peter Lichtlen is an academic researcher. The author has contributed to research in topics: Gastrointestinal motility and disorders & Gastroesophageal reflux and treatments & Trace Elements in Health. The author has an h-index of 21, co-authored 87 publications.
ORCID: 0009-0002-3441-0553Papers by this author
worksCapsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation
2021 · Advances in Therapy · 1 citations
https://doi.org/10.1007/s12325-021-01707-9
Correction to: Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation
2021 · Advances in Therapy · 0 citations
https://doi.org/10.1007/s12325-021-01776-w
MY006, a half-life extended trispecific IgG4 antibody for the prevention of allergic reactions to peanut
2026 · Journal of Allergy and Clinical Immunology · 0 citations
https://doi.org/10.1016/j.jaci.2025.12.463
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat